Overview
Medical device maker's 2025 sales grew 19.5%, driven by 23.2% rise in medical sales
Q4 sales slightly missed analyst expectations
Company faced $6.3 mln labor inefficiencies at AJR facility, expects continued progress
Outlook
Company plans to add a new facility in Dominican Republic in Q2 2026
UFP Technologies expects significant growth in Safe Patient Handling market in 2026
Company remains bullish about future due to new talent and contract extensions
Result Drivers
MEDICAL SALES GROWTH - Co's 2025 revenue growth was driven by a 23.2% increase in medical sales
LABOR INEFFICIENCIES - Co absorbed $6.3 mln in labor-related inefficiencies at AJR facility, impacting FY earnings
Company press release: ID:nGNX2tGqQV
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Sales | Slight Miss* | $148.92 mln | $149.07 mln (4 Analysts) |
Q4 EPS | $2.28 | ||
Q4 Net Income | $17.57 mln | ||
Q4 Gross Profit | $41.97 mln | ||
Q4 Operating Income | $21.50 mln |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for UFP Technologies Inc is $329.50, about 36.3% above its February 23 closing price of $241.79
The stock recently traded at 24 times the next 12-month earnings vs. a P/E of 20 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments